Rapid column-switching liquid chromatography/mass spectrometric assay for DHEA-sulfate in the plasma of patients with alzheimer's disease

Sung Hee Cho, Byung Hwa Jung, Wonyong Lee, Bong Chul Chung

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A simple and highly sensitive method for the quantification of dehydroepiandrosterone-3-sulfate (DHEAS) in human plasma was developed. DHEAS was directly determined in plasma using column-switching liquid chromatography/mass spectrometry (LC-MS). The plasma was filtered with a membrane filter. The filtrate was injected onto a pre-column without further sample preparation such as extraction or derivatization. The pre-colunin was washed with an aqueous solution to remove interference and the analyte was eluted into a reversed-phase C18 analytical column for separation and detection using a column-switching valve. The calibration range of DHEAS was 0.01-10 μmol/L, and the linearity of the method was 0.999. The limit of detection (LOD) at a signal-to-noise (S/ N) ratio of 3 was 5 mnol/L. The accuracy and precision (% CV) were less than 10% in within-day and day-to-day variations. To explore the relationship between Alzheimer's disease and the DHEAS level in human plasma, the concentrations of DHEAS in female patients with Alzheimer's disease (n = 20) and in normal female subjects (n = 20) were measured. The level of DHEAS was significantly decreased in the plasma of patients with Alzheimer's disease (p < 0.0002) compared with that in normal subjects. From the results, we concluded that our method is sufficiently sensitivity and reliability for the quantification of DHEAS in clinical samples. Plasma DHEAS concentration could be an important marker to understand the pathogenesis of Alzheimer's disease.

Original languageEnglish
Pages (from-to)1093-1097
Number of pages5
JournalBiomedical Chromatography
Volume20
Issue number10
DOIs
Publication statusPublished - 2006 Oct 1

Fingerprint

Dehydroepiandrosterone Sulfate
Dehydroepiandrosterone
Liquid chromatography
Liquid Chromatography
Sulfates
Assays
Alzheimer Disease
Plasmas
Plasma (human)
Signal-To-Noise Ratio
Calibration
Mass spectrometry
Limit of Detection
Mass Spectrometry
Signal to noise ratio
Membranes

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Biochemistry
  • Molecular Biology
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

@article{8488c88fc03f4ca18e0f3f2467e56b90,
title = "Rapid column-switching liquid chromatography/mass spectrometric assay for DHEA-sulfate in the plasma of patients with alzheimer's disease",
abstract = "A simple and highly sensitive method for the quantification of dehydroepiandrosterone-3-sulfate (DHEAS) in human plasma was developed. DHEAS was directly determined in plasma using column-switching liquid chromatography/mass spectrometry (LC-MS). The plasma was filtered with a membrane filter. The filtrate was injected onto a pre-column without further sample preparation such as extraction or derivatization. The pre-colunin was washed with an aqueous solution to remove interference and the analyte was eluted into a reversed-phase C18 analytical column for separation and detection using a column-switching valve. The calibration range of DHEAS was 0.01-10 μmol/L, and the linearity of the method was 0.999. The limit of detection (LOD) at a signal-to-noise (S/ N) ratio of 3 was 5 mnol/L. The accuracy and precision ({\%} CV) were less than 10{\%} in within-day and day-to-day variations. To explore the relationship between Alzheimer's disease and the DHEAS level in human plasma, the concentrations of DHEAS in female patients with Alzheimer's disease (n = 20) and in normal female subjects (n = 20) were measured. The level of DHEAS was significantly decreased in the plasma of patients with Alzheimer's disease (p < 0.0002) compared with that in normal subjects. From the results, we concluded that our method is sufficiently sensitivity and reliability for the quantification of DHEAS in clinical samples. Plasma DHEAS concentration could be an important marker to understand the pathogenesis of Alzheimer's disease.",
author = "Cho, {Sung Hee} and Jung, {Byung Hwa} and Wonyong Lee and Chung, {Bong Chul}",
year = "2006",
month = "10",
day = "1",
doi = "10.1002/bmc.647",
language = "English",
volume = "20",
pages = "1093--1097",
journal = "Biomedical Chromatography",
issn = "0269-3879",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

Rapid column-switching liquid chromatography/mass spectrometric assay for DHEA-sulfate in the plasma of patients with alzheimer's disease. / Cho, Sung Hee; Jung, Byung Hwa; Lee, Wonyong; Chung, Bong Chul.

In: Biomedical Chromatography, Vol. 20, No. 10, 01.10.2006, p. 1093-1097.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rapid column-switching liquid chromatography/mass spectrometric assay for DHEA-sulfate in the plasma of patients with alzheimer's disease

AU - Cho, Sung Hee

AU - Jung, Byung Hwa

AU - Lee, Wonyong

AU - Chung, Bong Chul

PY - 2006/10/1

Y1 - 2006/10/1

N2 - A simple and highly sensitive method for the quantification of dehydroepiandrosterone-3-sulfate (DHEAS) in human plasma was developed. DHEAS was directly determined in plasma using column-switching liquid chromatography/mass spectrometry (LC-MS). The plasma was filtered with a membrane filter. The filtrate was injected onto a pre-column without further sample preparation such as extraction or derivatization. The pre-colunin was washed with an aqueous solution to remove interference and the analyte was eluted into a reversed-phase C18 analytical column for separation and detection using a column-switching valve. The calibration range of DHEAS was 0.01-10 μmol/L, and the linearity of the method was 0.999. The limit of detection (LOD) at a signal-to-noise (S/ N) ratio of 3 was 5 mnol/L. The accuracy and precision (% CV) were less than 10% in within-day and day-to-day variations. To explore the relationship between Alzheimer's disease and the DHEAS level in human plasma, the concentrations of DHEAS in female patients with Alzheimer's disease (n = 20) and in normal female subjects (n = 20) were measured. The level of DHEAS was significantly decreased in the plasma of patients with Alzheimer's disease (p < 0.0002) compared with that in normal subjects. From the results, we concluded that our method is sufficiently sensitivity and reliability for the quantification of DHEAS in clinical samples. Plasma DHEAS concentration could be an important marker to understand the pathogenesis of Alzheimer's disease.

AB - A simple and highly sensitive method for the quantification of dehydroepiandrosterone-3-sulfate (DHEAS) in human plasma was developed. DHEAS was directly determined in plasma using column-switching liquid chromatography/mass spectrometry (LC-MS). The plasma was filtered with a membrane filter. The filtrate was injected onto a pre-column without further sample preparation such as extraction or derivatization. The pre-colunin was washed with an aqueous solution to remove interference and the analyte was eluted into a reversed-phase C18 analytical column for separation and detection using a column-switching valve. The calibration range of DHEAS was 0.01-10 μmol/L, and the linearity of the method was 0.999. The limit of detection (LOD) at a signal-to-noise (S/ N) ratio of 3 was 5 mnol/L. The accuracy and precision (% CV) were less than 10% in within-day and day-to-day variations. To explore the relationship between Alzheimer's disease and the DHEAS level in human plasma, the concentrations of DHEAS in female patients with Alzheimer's disease (n = 20) and in normal female subjects (n = 20) were measured. The level of DHEAS was significantly decreased in the plasma of patients with Alzheimer's disease (p < 0.0002) compared with that in normal subjects. From the results, we concluded that our method is sufficiently sensitivity and reliability for the quantification of DHEAS in clinical samples. Plasma DHEAS concentration could be an important marker to understand the pathogenesis of Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=33750686950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750686950&partnerID=8YFLogxK

U2 - 10.1002/bmc.647

DO - 10.1002/bmc.647

M3 - Article

VL - 20

SP - 1093

EP - 1097

JO - Biomedical Chromatography

JF - Biomedical Chromatography

SN - 0269-3879

IS - 10

ER -